Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated June 2026
Many men reach a frustrating wall. Testosterone levels are optimized, blood work looks good, yet sexual desire has not returned. They try Viagra or Cialis, sometimes with partial success, but the deeper problem - the absence of the urge itself - does not improve with vascular drugs. If that describes you, bremelanotide (PT-141) may be the next conversation to have with your prescribing physician.
PT-141 is not a biohacking novelty. It is a clinically studied melanocortin receptor agonist that targets the brain's arousal pathways directly. Its commercial form, Vyleesi, was FDA-approved in 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD). But sexual medicine specialists - including Drs. Sue and Irwin Goldstein and Dr. Abraham Morgentaler - have been using it off-label in men for years, with outcomes data that is worth understanding.
This article explains how PT-141 works, what the clinical evidence shows for men specifically, how dosing is approached, what side effects to expect, and who is most likely to benefit. It draws on published research, specialty clinic outcomes, and years of real-world experience reported by the ExcelMale community.
What You Will Learn:
PT-141 works differently because it targets the neurological software. As a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), it acts as an agonist at MC3-R and MC4-R receptors in the hypothalamus - the brain region responsible for sexual motivation. Activation of MC4-R triggers dopaminergic signaling in the medial preoptic area, which is the brain's primary control center for sexual drive. This creates the urge itself, not just the physical response to an urge that is already present.
This is not just a conceptual distinction. An fMRI study demonstrated that bremelanotide improved connectivity between the amygdala and insula during visual sexual stimulation, enhanced cerebellar activity, and altered secondary somatosensory cortex activity compared to placebo. The drug changes how the brain processes sexual information, not merely how the body responds to it.
Research by Reddy, Khoei, and Khera also suggests PT-141 may trigger the release of oxytocin - the neuropeptide linked to bonding and emotional connection. This may explain why many men report not just improved erections but a qualitatively better overall experience, including heightened sensitivity and a more natural connection between desire and physical response.
Table 1: Mechanism Comparison - PT-141, PDE5 Inhibitors, and Trimix
Key findings from the Goldstein and Khera clinical cohorts:
A separate clinical study evaluated men with ED who had not responded adequately to sildenafil. In the PT-141 group, 34% achieved and maintained an erection sufficient for intercourse, compared to just 9% in the placebo group. This is a statistically significant result in a population considered treatment-resistant under standard protocols.
Palatin Technologies - the developer of bremelanotide - initiated a Phase 2 clinical trial in 2023 investigating a co-formulated bremelanotide plus PDE5 inhibitor in a single injection, specifically targeting men who do not respond to PDE5i monotherapy. Phase 3 planning followed pending IND acceptance with the FDA. The rationale is clear: approximately 30-40% of ED patients exhibit little or no adequate response to PDE5 inhibitors alone. For this population, the central pathway has been underaddressed.
Table 2: Clinical Outcomes in Men Using Bremelanotide Off-Label (Goldstein / Khera Cohorts)
Standard off-label dosing protocol for men:
Micro-dosing - what the ExcelMale community learned:
ExcelMale member Cataceous documented a detailed micro-dosing experiment using 15-20 mcg injected five times daily. The rationale: standard PT-141 doses may represent massive overstimulation relative to endogenous alpha-MSH levels. Results during the first four days were striking - sustained high libido throughout the day, easy erections in response to minimal stimulation, and a qualitative experience described as far superior to single large-dose use.
However, the protocol revealed critical limitations. The response diminished rapidly after the first few days (a honeymoon effect). Prolonged continuous use produced a paradoxical drop in libido below baseline. And the CNS stimulation came with consistent sleep disruption - averaging a 30-40 minute reduction per night.
The conclusion: tolerance develops with PT-141 regardless of dosing strategy. A dosing holiday of 1-2 weeks appears to restore response in most cases. PT-141 is not a medication designed for continuous daily use.
Table 3: PT-141 Dosing Strategies - Standard vs. Experimental
Common side effects and clinical incidence rates:
Hyperpigmentation - the dose-frequency risk: Exceeding 8 doses per month meaningfully increases the risk of skin darkening or blotchy discoloration. This is a direct consequence of melanocortin receptor activation. Staying within the monthly limit effectively eliminates this risk for most users.
Source quality - a non-negotiable safety point: PT-141 obtained through gray-market chemical suppliers, online peptide vendors without pharmacy oversight, or overseas platforms carries serious risks including impurities, contamination, non-sterile preparation, and inconsistent concentration. Any compounded PT-141 should come from a licensed compounding pharmacy with prescription documentation.
PT-141 is less likely to be sufficient as monotherapy when dysfunction is predominantly vascular - arterial insufficiency, severe diabetes-related neuropathy, or post-prostatectomy ED. In those cases, the central signal may be intact, but the downstream plumbing cannot respond adequately. Combination approaches become relevant in that setting.
A thorough biopsychosocial evaluation - assessing desire patterns, mental health, relationship quality, prior treatment history, and vascular risk - is the standard used by sexual medicine specialists to identify ideal candidates.
Published evidence supports this approach. A study by Diamond et al. showed that co-administration of low-dose intranasal PT-141 and sildenafil in men with ED produced an enhanced erectile response significantly greater than sildenafil alone. In another study, men who were partial responders to sildenafil or vardenafil showed greater erectile response when PT-141 was added.
Palatin Technologies' Phase 2 trial launched in 2024 tested exactly this approach - a co-formulated bremelanotide plus PDE5 inhibitor single injection - in the PDE5i non-responder population. If Phase 3 results confirm the Phase 2 data, an FDA-approved combination product targeting male ED may eventually become available.
For men with severe vascular dysfunction that does not respond even to combination oral therapy, Trimix (a direct intracavernosal injection of papaverine, phentolamine, and alprostadil) can be used alongside PT-141. This represents the most aggressive combination approach and is typically reserved for men who have exhausted monotherapy and dual-therapy options.
The practical limitations are real: nausea is common, injection is required, and individual response varies. Starting low (0.5 mg), timing the injection properly, and working with a prescribing physician who understands the medication's mechanism and safety guidelines makes the difference between a positive experience and early discontinuation.
If you are on TRT, have optimized your protocol, and still find that desire and erection quality are falling short, PT-141 is worth a serious conversation with your prescribing physician. It is also worth exploring combination approaches if partial PDE5i response is the pattern you have experienced.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Bremelanotide (PT-141) is FDA-approved only for premenopausal women with HSDD; its use in men is off-label. Always consult a qualified healthcare provider before starting or modifying any hormone therapy, peptide therapy, or medical treatment. Individual responses vary. Side effects described in this article are based on available clinical data and community reports and may not reflect every patient's experience.
About ExcelMale.com
ExcelMale.com is one of the longest-running men's health forums on the internet, with over 24,000 members and more than 20 years of peer-reviewed, community-tested health information. Founded by Nelson Vergel - chemical engineer, 34-year TRT veteran, and patient advocate - ExcelMale covers testosterone replacement therapy, hormone optimization, peptides, sexual health, blood work interpretation, and related men's health topics. Nelson is the author of Testosterone: A Man's Guide and Beyond Testosterone. For lab testing, visit DiscountedLabs.com.
Many men reach a frustrating wall. Testosterone levels are optimized, blood work looks good, yet sexual desire has not returned. They try Viagra or Cialis, sometimes with partial success, but the deeper problem - the absence of the urge itself - does not improve with vascular drugs. If that describes you, bremelanotide (PT-141) may be the next conversation to have with your prescribing physician.
PT-141 is not a biohacking novelty. It is a clinically studied melanocortin receptor agonist that targets the brain's arousal pathways directly. Its commercial form, Vyleesi, was FDA-approved in 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD). But sexual medicine specialists - including Drs. Sue and Irwin Goldstein and Dr. Abraham Morgentaler - have been using it off-label in men for years, with outcomes data that is worth understanding.
This article explains how PT-141 works, what the clinical evidence shows for men specifically, how dosing is approached, what side effects to expect, and who is most likely to benefit. It draws on published research, specialty clinic outcomes, and years of real-world experience reported by the ExcelMale community.
What You Will Learn:
- Why PT-141 acts on the brain rather than blood flow - and why that distinction matters for men who have not responded to PDE5 inhibitors
- What clinical data shows about success rates in men with low desire and erectile dysfunction
- How dosing works, from standard off-label protocols to the micro-dosing approach documented in the ExcelMale community
- Which side effects are common, how severe they typically are, and how to manage them
- Who is the ideal candidate and when combining PT-141 with other treatments makes sense
| Key Takeaways |
|---|
| • PT-141 (bremelanotide) is a melanocortin receptor agonist that works in the brain to generate sexual desire - not a vascular drug like Viagra or Cialis. |
| • FDA-approved as Vyleesi for women with HSDD; off-label use in men is supported by clinical data and specialty practice. |
| • Standard starting dose for men is 0.5-1 mg subcutaneously, injected 30-90 minutes before sexual activity. Starting low significantly reduces nausea. |
| • Nausea (30-36%) and flushing (22-36%) are the most common side effects; both typically diminish with repeated use. |
| • PT-141 can be combined with PDE5 inhibitors or Trimix; published data shows the combination outperforms either therapy alone. |
| • Tolerance develops with repeated use. A 1-2 week dosing holiday typically restores response. |
| • Do not exceed 8 doses per month. Overuse increases the risk of skin hyperpigmentation. |
Why Does PT-141 Work on the Brain Instead of Blood Flow?
PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) work by relaxing smooth muscle in penile blood vessels, increasing blood flow once arousal has already begun. They address the hardware. They cannot create arousal from scratch. When the brain is not generating the signal to want sex in the first place, adding more blood flow does not fix the underlying problem.PT-141 works differently because it targets the neurological software. As a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), it acts as an agonist at MC3-R and MC4-R receptors in the hypothalamus - the brain region responsible for sexual motivation. Activation of MC4-R triggers dopaminergic signaling in the medial preoptic area, which is the brain's primary control center for sexual drive. This creates the urge itself, not just the physical response to an urge that is already present.
This is not just a conceptual distinction. An fMRI study demonstrated that bremelanotide improved connectivity between the amygdala and insula during visual sexual stimulation, enhanced cerebellar activity, and altered secondary somatosensory cortex activity compared to placebo. The drug changes how the brain processes sexual information, not merely how the body responds to it.
Research by Reddy, Khoei, and Khera also suggests PT-141 may trigger the release of oxytocin - the neuropeptide linked to bonding and emotional connection. This may explain why many men report not just improved erections but a qualitatively better overall experience, including heightened sensitivity and a more natural connection between desire and physical response.
Table 1: Mechanism Comparison - PT-141, PDE5 Inhibitors, and Trimix
| Feature | PT-141 (Bremelanotide) | PDE5 Inhibitors (Viagra/Cialis) | Trimix (Injection) |
|---|---|---|---|
| Primary target | Central nervous system (MC3-R / MC4-R receptors) | Vascular system (PDE5 enzyme inhibition) | Local penile tissue (direct injection) |
| Neurochemical effect | Raises dopamine; may trigger oxytocin release | Enhances nitric oxide pathways | Papaverine / phentolamine / alprostadil |
| Improves libido? | Yes - primary mechanism | No (requires existing arousal) | No (mechanical only) |
| Works without stimulation? | Yes - ideation-based erections possible | No - requires some arousal first | Yes - mechanical; no arousal needed |
| Duration of window | Up to 72 hours of arousal capacity | 4-6 hrs (sildenafil) / 36 hrs (tadalafil) | 1-2 hours per injection |
| For PDE5 non-responders? | Often effective; targets different pathway | First-line; ~30-40% non-responder rate | Second/third line for severe ED |
| Administration | Subcutaneous injection | Oral tablet | Intracavernosal injection |
What Do Clinical Studies Show About PT-141 for Men with Low Libido or ED?
The strongest clinical evidence for PT-141 in men comes from specialized sexual medicine clinics, most notably those led by Drs. Sue and Irwin Goldstein in San Diego. Their outcomes data, reviewed by specialists including Dr. Mohit Khera and Dr. Abraham Morgentaler, shows results that vascular therapies alone cannot match for certain patient profiles.Key findings from the Goldstein and Khera clinical cohorts:
- 91% of men experienced measurable improvement in overall sexual function
- 100% of participants presenting with low sexual desire or sexual anxiety reported significant improvement
- 88-93% reported easier penetration during intercourse
- 67-71% found it easier to reach orgasm
- 73-79% reported that their partners experienced a more pleasurable encounter
- 69% of enrolled participants were originally seeking treatment for erectile dysfunction - yet responded to a centrally acting drug, suggesting their dysfunction had a neurological component being missed by vascular therapy alone
A separate clinical study evaluated men with ED who had not responded adequately to sildenafil. In the PT-141 group, 34% achieved and maintained an erection sufficient for intercourse, compared to just 9% in the placebo group. This is a statistically significant result in a population considered treatment-resistant under standard protocols.
Palatin Technologies - the developer of bremelanotide - initiated a Phase 2 clinical trial in 2023 investigating a co-formulated bremelanotide plus PDE5 inhibitor in a single injection, specifically targeting men who do not respond to PDE5i monotherapy. Phase 3 planning followed pending IND acceptance with the FDA. The rationale is clear: approximately 30-40% of ED patients exhibit little or no adequate response to PDE5 inhibitors alone. For this population, the central pathway has been underaddressed.
Table 2: Clinical Outcomes in Men Using Bremelanotide Off-Label (Goldstein / Khera Cohorts)
| Outcome Measure | Improvement Rate | Clinical Note |
|---|---|---|
| Overall sexual function improvement | 91% | All improved patients also showed erectile improvement |
| Low sexual desire / sexual anxiety | 100% | Complete resolution of desire and anxiety complaints |
| Ease of penetration / intercourse | 88-93% | Consistent across desire-focused and ED-focused patients |
| Ease of reaching orgasm | 67-71% | Central mechanism supports the full arousal-to-orgasm pathway |
| Partner satisfaction improvement | 73-79% | Quality-of-life impact extends to relational outcomes |
| Erections in PDE5i non-responders | 34% vs 9% placebo | Phase 2a study; statistically significant result |
What Is the Right Starting Dose of PT-141 for Men?
PT-141 is administered via subcutaneous injection into the abdomen or thigh. It does not survive the digestive environment, making oral delivery ineffective. Sublingual troches, while common in compounding, often underperform because the peptide may be partially swallowed or absorbed inconsistently through oral mucosa. Subcutaneous injection remains the gold standard for reliable blood levels.Standard off-label dosing protocol for men:
- Starting dose: 0.5 mg to 1 mg. Beginning at the lower end dramatically reduces nausea risk while still allowing the medication to take effect
- Typical clinical range: 1 mg to 2 mg per dose (mirroring the FDA-approved 1.75 mg dose for women)
- Timing: Inject 30 to 90 minutes before anticipated sexual activity; some individuals notice onset later, at several hours post-injection
- Frequency: No more than once per 24-hour period
- Monthly cap: 8 doses per month maximum - exceeding this threshold significantly increases hyperpigmentation risk
Micro-dosing - what the ExcelMale community learned:
ExcelMale member Cataceous documented a detailed micro-dosing experiment using 15-20 mcg injected five times daily. The rationale: standard PT-141 doses may represent massive overstimulation relative to endogenous alpha-MSH levels. Results during the first four days were striking - sustained high libido throughout the day, easy erections in response to minimal stimulation, and a qualitative experience described as far superior to single large-dose use.
However, the protocol revealed critical limitations. The response diminished rapidly after the first few days (a honeymoon effect). Prolonged continuous use produced a paradoxical drop in libido below baseline. And the CNS stimulation came with consistent sleep disruption - averaging a 30-40 minute reduction per night.
The conclusion: tolerance develops with PT-141 regardless of dosing strategy. A dosing holiday of 1-2 weeks appears to restore response in most cases. PT-141 is not a medication designed for continuous daily use.
Table 3: PT-141 Dosing Strategies - Standard vs. Experimental
| Protocol | Dose / Frequency | Target Outcome | Key Limitations |
|---|---|---|---|
| FDA-standard (off-label for men) | 1-2 mg subcutaneously as needed | Acute on-demand; 72-hour arousal window | Higher nausea, flushing, headache |
| Low-dose start | 0.5 mg; titrate up if tolerated | Reduced side effects; gauge sensitivity | May produce weaker initial response |
| Micro-dosing (high-intensity) | 20 mcg x 5 times daily | Sustained libido; ideation-based arousal | Rapid tolerance; sleep disruption; overstimulation |
| Low-dose micro-dosing | 10-15 mcg x 5 times daily | Maintenance attempt; fewer side effects | Generally insufficient to maintain threshold |
| Maintenance (some prescribers) | 300 mcg twice weekly | Baseline libido support | Limited published data; variable response |
What Side Effects Should Men Expect from PT-141 Injections?
PT-141's side effects are often described as front-loaded - more intense on the first few uses and frequently diminishing with repeated exposure. Understanding what to expect makes the difference between persisting through a potentially effective treatment and abandoning it prematurely.Common side effects and clinical incidence rates:
- Nausea: 30-36% of users. The primary reason for discontinuation, but many men report significant reduction after 2-3 doses. Injecting on a full stomach and starting at 0.5 mg reduces severity
- Facial flushing: 22-36%. A warm redness of the face and upper chest; typically transient, lasting a few hours
- Headache: 13-27%. Acute onset following injection; usually resolves as the drug metabolizes
- Spontaneous erections without stimulation: 13-27%. Can persist for up to 24 hours post-injection. These are transient, not priapism, but require patient preparation
- Sinus congestion and body aches: Common; frequently described as among the most bothersome persistent effects
- Temporary blood pressure elevation: Documented; warrants additional caution in men with hypertension or cardiovascular risk
- Abdominal burning, cramping, mild incontinence: Each reported in approximately 4% of users
Hyperpigmentation - the dose-frequency risk: Exceeding 8 doses per month meaningfully increases the risk of skin darkening or blotchy discoloration. This is a direct consequence of melanocortin receptor activation. Staying within the monthly limit effectively eliminates this risk for most users.
Source quality - a non-negotiable safety point: PT-141 obtained through gray-market chemical suppliers, online peptide vendors without pharmacy oversight, or overseas platforms carries serious risks including impurities, contamination, non-sterile preparation, and inconsistent concentration. Any compounded PT-141 should come from a licensed compounding pharmacy with prescription documentation.
Who Is the Best Candidate for PT-141 Off-Label Treatment?
Based on clinical outcomes data and the patient profiles from specialized sexual medicine clinics, PT-141 is most likely to benefit men in these categories:- Hypoactive sexual desire disorder (HSDD): Absent or very low sex drive that persists even with optimized testosterone levels
- Psychogenic erectile dysfunction or performance anxiety: When the physical apparatus is functional but the brain-body connection is disrupted by anxiety or psychological factors
- Optimized TRT with persistent low libido: Testosterone is in range, estradiol is controlled, blood work is solid - yet desire and erection quality still underperform
- Partial PDE5 inhibitor response: Men who get some benefit from Viagra or Cialis but not full, satisfying results
- PDE5 inhibitor non-responders: Particularly compelling given that 34% of this population achieved sufficient erections in clinical trials versus 9% on placebo
- Anorgasmia: Difficulty reaching climax. PT-141's central mechanism supports the full arousal-to-orgasm pathway
PT-141 is less likely to be sufficient as monotherapy when dysfunction is predominantly vascular - arterial insufficiency, severe diabetes-related neuropathy, or post-prostatectomy ED. In those cases, the central signal may be intact, but the downstream plumbing cannot respond adequately. Combination approaches become relevant in that setting.
A thorough biopsychosocial evaluation - assessing desire patterns, mental health, relationship quality, prior treatment history, and vascular risk - is the standard used by sexual medicine specialists to identify ideal candidates.
Can PT-141 Be Combined with Viagra, Cialis, or Other ED Treatments?
Yes, and the combination is often more effective than either therapy alone. The mechanistic logic is straightforward: PT-141 drives the central signal (desire and ideation), while PDE5 inhibitors optimize the peripheral vascular response (blood flow). These two drugs act on entirely different pathways, making their effects potentially additive rather than redundant.Published evidence supports this approach. A study by Diamond et al. showed that co-administration of low-dose intranasal PT-141 and sildenafil in men with ED produced an enhanced erectile response significantly greater than sildenafil alone. In another study, men who were partial responders to sildenafil or vardenafil showed greater erectile response when PT-141 was added.
Palatin Technologies' Phase 2 trial launched in 2024 tested exactly this approach - a co-formulated bremelanotide plus PDE5 inhibitor single injection - in the PDE5i non-responder population. If Phase 3 results confirm the Phase 2 data, an FDA-approved combination product targeting male ED may eventually become available.
For men with severe vascular dysfunction that does not respond even to combination oral therapy, Trimix (a direct intracavernosal injection of papaverine, phentolamine, and alprostadil) can be used alongside PT-141. This represents the most aggressive combination approach and is typically reserved for men who have exhausted monotherapy and dual-therapy options.
Frequently Asked Questions About PT-141 for Men
Is PT-141 legal for men to use in the United States?
PT-141 (bremelanotide) is FDA-approved as Vyleesi only for premenopausal women with HSDD. Its use in men is off-label, which is completely legal when prescribed by a licensed physician - off-label prescribing is a standard and well-established medical practice. Many compounding pharmacies supply bremelanotide at significantly lower cost than the brand-name Vyleesi (which was priced at $899 for a four-pack at launch). Obtaining it without a prescription through gray-market sources carries both safety and legal risks and is strongly discouraged.How quickly does PT-141 work, and how long do the effects last?
Most men notice effects between 45 minutes and a few hours after injection. The window of enhanced arousal capacity can extend up to 72 hours, which is one of PT-141's most practical advantages over oral PDE5 inhibitors. Spontaneous, unstimulated erections are most common in the first 18-24 hours post-injection and tend to diminish as the drug metabolizes. The 72-hour window refers to arousal readiness when stimulated, not continuous or unprovoked erection.Does PT-141 work if testosterone levels are low?
Optimizing testosterone first is recommended. Low testosterone independently impairs libido through mechanisms separate from the melanocortin pathway. PT-141 is most effective when baseline testosterone is at an adequate therapeutic level. Men on TRT who have optimized their protocol but still experience poor desire are the population most likely to see meaningful benefit from PT-141 as an adjunct treatment.Will nausea improve with repeated PT-141 use?
Many men report that nausea diminishes substantially after the first 2-3 exposures. Starting at a lower dose (0.5 mg rather than 1.75 mg) and injecting after a full meal can reduce initial severity. If nausea remains intolerable at standard doses, a lower-frequency or lower-dose protocol may be worth exploring with your prescribing physician. Some men find that taking an anti-nausea medication approximately 30 minutes before the PT-141 injection also helps.Can PT-141 cause permanent skin darkening?
Temporary flushing (warmth and redness) is common and fully transient. Persistent hyperpigmentation - blotchy or darkened areas on the skin - is associated with exceeding 8 doses per month. This occurs because melanocortin receptors influence both sexual signaling and pigmentation. Staying within the recommended monthly frequency essentially eliminates this risk. Men who notice skin changes should discuss frequency reduction with their prescribing physician.Conclusion
PT-141 represents a genuine clinical advance for a subset of men where conventional treatment has not worked. When the problem is not the plumbing but the signal - when desire itself is absent or suppressed - addressing the neurological software rather than the vascular hardware is the logical next step. The data supports this. A 91% overall improvement rate and 100% resolution of low desire in clinical cohorts are not numbers generated by placebo effect in a motivated population.The practical limitations are real: nausea is common, injection is required, and individual response varies. Starting low (0.5 mg), timing the injection properly, and working with a prescribing physician who understands the medication's mechanism and safety guidelines makes the difference between a positive experience and early discontinuation.
If you are on TRT, have optimized your protocol, and still find that desire and erection quality are falling short, PT-141 is worth a serious conversation with your prescribing physician. It is also worth exploring combination approaches if partial PDE5i response is the pattern you have experienced.
Related ExcelMale Forum Discussions
- PT-141 (Bremelanotide) for Men - Dosing, Libido, and What the Research Shows - Comprehensive overview of PT-141 clinical evidence, community experience, and protocol guidance for men on TRT
- Off-Label Use of Bremelanotide (PT-141) in Men: Insights on Libido, Erections, and Safety from Experts - Video discussion with Dr. Brandon and Dr. Abraham Morgentaler on off-label bremelanotide use and compounding access
- PT-141 (Bremelanotide) for Improved Sex Drive (Libido) and Erections - Detailed first-person community reports on onset time, erection quality, nausea, and long-term use patterns
- Use of the CNS Agent Bremelanotide (PT-141) in Men with Sexual Dysfunction - Clinical study abstract and discussion including fMRI data on brain connectivity changes
- The Amazing Bremelanotide PT-141 (Vyleesi) - Cost and Access Discussion - Community thread on pricing, compounding pharmacy access, and real-world tolerability observations
- PT-141 Bremelanotide - Community Experiences and Combination Protocols - Members share personal protocols, combination strategies with Viagra and Cialis, and tips for managing side effects
Key References
- Goldstein S, Goldstein I, et al. Use of Bremelanotide (Vyleesi) PT-141 in Men with Sexual Dysfunctions. Journal of Sexual Medicine, 2024. View study
- Stern N, Bajic P, Campbell J, et al. Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sexual Medicine Reviews. 2025;13(4):513-537. DOI link
- Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65:755-759. DOI link
- Reddy AG, Khoei S, Khera M. Bremelanotide in men with sexual dysfunction. Current Sexual Health Reports, 2021. DOI link
- Palatin Technologies, Inc. Palatin initiates clinical program for bremelanotide co-formulated with a PDE5i for treatment of ED in PDE5i non-responsive patients. Press Release, August 2023. View release
- Palatin Technologies, Inc. Palatin announces initiation of Phase 2 clinical study of bremelanotide co-administered with a PDE5i for the treatment of ED. Press Release, June 2024. View release
- Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019;79:1599-1606. DOI link
- Clayton AH, Kingsberg SA, Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sexual Medicine. 2018;6(2):59-74. DOI link
- Uckert S, Elst M, Schrader M, Oelke M. Phosphodiesterase inhibitors in sexual medicine: novel pharmacological perspectives. World Journal of Men's Health. 2021;39:1-12. DOI link
- FDA News Release. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. U.S. Food and Drug Administration, June 2019. View release
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Bremelanotide (PT-141) is FDA-approved only for premenopausal women with HSDD; its use in men is off-label. Always consult a qualified healthcare provider before starting or modifying any hormone therapy, peptide therapy, or medical treatment. Individual responses vary. Side effects described in this article are based on available clinical data and community reports and may not reflect every patient's experience.
About ExcelMale.com
ExcelMale.com is one of the longest-running men's health forums on the internet, with over 24,000 members and more than 20 years of peer-reviewed, community-tested health information. Founded by Nelson Vergel - chemical engineer, 34-year TRT veteran, and patient advocate - ExcelMale covers testosterone replacement therapy, hormone optimization, peptides, sexual health, blood work interpretation, and related men's health topics. Nelson is the author of Testosterone: A Man's Guide and Beyond Testosterone. For lab testing, visit DiscountedLabs.com.
